Cargando…
Beyond post-marketing research and MedWatch: Long-term studies of drug risks
Critics of the drug safety system have discussed many different potential reforms, ranging from mandatory registration of clinical trials to increasing the power of regulatory agencies, but few have discussed one of the most important ways of enhancing safety: increasing the number of long-term stud...
Autor principal: | Resnik, David B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763348/ https://www.ncbi.nlm.nih.gov/pubmed/19727333 |
Ejemplares similares
-
No Relationship of Anti-Androgens to Alzheimer’s Disease or Cognitive Disorder in the MedWatch Database
por: Lehrer, Steven, et al.
Publicado: (2018) -
Alzheimer’s Disease and Intranasal Fluticasone Propionate in the FDA MedWatch Adverse Events Database
por: Lehrer, Steven, et al.
Publicado: (2018) -
Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
por: Duprey, Matthew S., et al.
Publicado: (2019) -
Reclaiming or rebranding marketing: implications beyond digital
por: Ritter, Thomas
Publicado: (2020) -
A Medwatch review of reported events in patients who discontinued rivaroxaban (XARELTO) therapy in response to legal advertising
por: Burton, Paul, et al.
Publicado: (2016)